The U.S. Food and Drug Administration Monday said Novartis AG's (NVS, NOVN.VX) multiple- sclerosis drug Gilenya shouldn't be used in patients with a recent history of stroke or some types of heart problems, concluding a safety review of the drug.
The safety review was prompted by a report last November of a 59-year-old patient dying in the U.S. less than 24 hours after taking the first dose of the drug.
Read the full story: http://hcp.lv/JZgxdd
Source: Morningstar
Cognitive Benefits in Multiple Sclerosis Seen After Transcranial Current Stimulation
November 17th 2023Patients with multiple sclerosis (MS) showed cognitive improvements with frontal theta-transcranial alternating current stimulation (tACS), suggesting its potential as a tolerable and beneficial intervention.
Read More
Internet-Based CBT Effective for Treating MS-Related Depression, Study Finds
October 24th 2023A phase 3, randomized, parallel-group trial showcased the efficacy of internet-based cognitive behavioral therapy (iCBT) for combatting depressive symptoms brought on by multiple sclerosis (MS).
Read More
FDA Allows At-Home Dosing of Intranasal Foralumab for Multiple Sclerosis
October 23rd 2023The FDA’s decision to allow at-home dosing of intransal foralumab for patients with multiple sclerosis is likely to improve patient compliance to treatment and health outcomes, according to a recent release statement.
Read More